Evidence map›Paper›PMID 42665764›Full record

ArticleMolecular diversity2026

Computational discovery of HIF-1α/VHL protein-protein interaction inhibitors for hypoxic cell protection.

Binglin Huang, Bijuan Lin, Xiao Chen, Yifan Zhu, Na Li, Bin Zheng, Weiwei Zheng, Xin Xue, Maobai Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Binglin Huang *Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Bijuan Lin *Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Xiao ChenNational and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Yifan ZhuNational and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Na LiDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Bin ZhengDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Weiwei ZhengDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Xin XueNational and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China. xuexin@njucm.edu.cn.
Maobai LiuSchool of Pharmacy, Fujian Medical University, Fuzhou, 350004, Fujian, China. liumb0591@fjmu.edu.cn.

Funding

Fujian Provincial Natural Science Foundation of China grant No. 2023J01649Fujian Provincial Natural Science Foundation of China grant No. 2026J001582Joint Funds for the innovation of science and Technology, Fujian province grant No.2021Y9051
6 · The paper itself

Abstract

The HIF-1α/VHL protein-protein interaction regulates cellular hypoxic adaptation. Targeting this PPI offers therapeutic potential for ischemia, yet the structural diversity and direct cytoprotective applications of reported VHL ligands remain limited. Here, we developed a computational virtual-screening workflow informed by deep learning-based interface analysis. DDMut-PPI was used to nominate putative auxiliary interface residues for construction of an alternative pharmacophore model. Screening of 24,893 molecules followed by fluorescence-polarization testing identified four candidates with IC

Indexed as

HIF-1α/VHLHypoxic cell protectionProtein–protein interactionSmall molecule inhibitorVirtual screening

Identifiers

PMID42665764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.